Paris (France) (AFP) – The anti-obesity Wegovy, until now offered in France as an injection, arrives this Monday in the form of tablets in pharmacies, a launch which comes as its Danish manufacturer Novo and its American rival Eli Lilly intensify their competition in this growing market.
Published on: 02/11/2026 - 09:47
This is the first drug in the GLP-1 class marketed in France in oral form. These treatments mimic the action of a gut hormone that regulates appetite and promotes weight loss.
Already available in the United States, the United Kingdom and Germany, the Wegovy pill (semaglutide) is offered in France on medical prescription to obese or overweight adults with at least one comorbidity linked to their weight.
When it was launched, the tablet was not covered by Health Insurance. And for the moment, the laboratory has not submitted a reimbursement request.
Patients will therefore have to pay 169 euros to 235 euros per month depending on the dosage, prices lower than those charged at the start of the first injectable GLP-1. These had also been marketed at a free price before being reimbursed in France since June for the most serious forms of obesity.
Several unknowns remain: “how many new patients will start using these medications?” and “how many will move from injectable to oral?”, raises Alexandre Fauconnier, from the Kearney consulting firm.
- “Additional therapeutic option” -
Nearly 100,000 overweight or obese patients already take Wegovy in France.
For Novo, “the tablet does not replace the injectable: it makes it possible to treat patients who were not treated before”. This is “an additional therapeutic option”.
Its authorization was granted based on the results of a clinical study showing an average weight loss close to 17% with the highest dose after approximately 15 months of treatment.
Eli Lilly is not to be outdone. Its oral treatment for obesity, orforglipron, has been marketed under the name Foundayo in the United States since April and in the United Kingdom since August.
Its arrival in Europe is expected soon, after the favorable opinion given in mid-October by the European Medicines Agency (EMA), the first step before its marketing authorization in the EU.
“The markets follow very closely the curves of the first prescriptions for obesity of the two products,” observes Mr. Fauconnier.
At this point, the Wegovy pill has taken a lead, generating sales of more than $480 million in the second quarter.
As of the end of September, more than 5 million prescriptions for this treatment have already been issued in the United States, according to Novo. And in the United Kingdom, the tablet sells “more than 65,000 boxes per week” on average.
Eli Lilly, leader in the injectable anti-obesity segment in the United States, however, intends to take advantage of Foundayo's ease of use ($98 million in sales in the second quarter). A product that can be swallowed at any time, with or without food.
Flexibility compared to the competing tablet, which must be taken every morning on an empty stomach with a little water. A period of at least 30 minutes must also be respected before eating, drinking or taking other medications.
New molecules in the pipes
To extend their hold on the anti-obesity market expected to exceed $100 billion by 2030, according to estimates, the two giants are working tirelessly on the next generations of treatments.
Several avenues for improvement are expected in terms of effectiveness, tolerance, dose spacing and even the preservation of muscle mass.
“Pills which will target, not one receptor, but several at the same time, with more effectiveness. Treatments which will also target complications linked to obesity”, underlines Laurent Palanque, partner in the firm OMS & Co.
Eyes are turning, for example, to Lilly's retatrutide, a molecule under development which activates 3 hormonal receptors (GIP, GLP-1 and glucagon), perceived by some experts as the potential "Rolls of its portfolio" of drugs.
As for Novo, it is developing a new generation anti-obesity drug (CagriSema) which combines semaglutide with another active ingredient, cagrilintide.
In the meantime, it is also releasing this Monday in France a high-dose version of Wegovy by injection (at 7.2 mg) to expand its offer.
In France, the medical and socio-economic cost of obesity is estimated at 18 billion euros per year, according to the Asterès firm, mandated by Novo Nordisk.
© 2026 AFP
The content you are trying to access does not exist or is no longer available.




